Key terms
About TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TGTX news
Mar 01
9:31am ET
TG Therapeutics presents data from ULTIMATE I & II, ENHANCE trials
Feb 29
7:45am ET
TG Therapeutics: A Strong Buy on Robust Briumvi Sales and Promising Pipeline Prospects
Feb 29
5:40am ET
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), TG Therapeutics (TGTX) and Amicus (FOLD)
Feb 28
5:42pm ET
TG Therapeutics price target raised to $13 from $12 at Goldman Sachs
Feb 28
12:05pm ET
Goldman Sachs Sticks to Their Hold Rating for TG Therapeutics (TGTX)
Feb 28
9:40am ET
Unusually active option classes on open February 28th
Feb 28
7:04am ET
TG Therapeutics reports Q4 EPS (9c), consensus (10c)
Feb 27
1:45pm ET
TG Therapeutics call volume above normal and directionally bullish
Feb 27
7:33am ET
TG Therapeutics announces issuance of additional patents for BRIUMVI
Feb 26
11:45am ET
TG Therapeutics: Promising European Expansion and Strong Financial Outlook Justify Buy Rating
Feb 26
7:20am ET
TG Therapeutics announces European launch of BRIUMVI
Feb 13
9:02am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Zoetis (ZTS) and Teladoc (TDOC)
Feb 12
7:11am ET
Precision gets initial $7.5M from TG Therapeutics for azer-cel development
Feb 12
7:11am ET
Precision gets initial $7.5M from TG Therapeutics for azer-cel development
Feb 05
11:20am ET
TG Therapeutics participates in a conference call with Cantor Fitzgerald
Feb 05
7:58am ET
TG Therapeutics price target raised to $29 from $24 at B. Riley
Feb 03
1:11pm ET
TG Therapeutics price target lowered to $22 from $23 at JPMorgan
Feb 02
12:45pm ET
Buy Rating Affirmed for TG Therapeutics on Strong Briumvi Sales and Favorable Market Dynamics
Jan 12
11:36am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
6:06am ET
TG Therapeutics price target raised to $45 from $41 at H.C. Wainwright
Jan 10
9:40am ET
Unusually active option classes on open January 10th
Jan 10
8:36am ET
TG Therapeutics (NASDAQ:TGTX) Surges After Preliminary Q4 and FY23 Results
Jan 10
7:04am ET
TG Therapeutics sees FY24 BRIUMVI U.S. revenue $220M-$260M
Jan 10
7:03am ET
TG Therapeutics reports preliminary FY23 BRIUMVI U.S. revenue $89M
Jan 10
7:03am ET
TG Therapeutics reports preliminary Q4 BRIUMVI U.S. revenue $40M
Jan 09
10:55pm ET
Goldman Sachs Sticks to Their Hold Rating for TG Therapeutics (TGTX)
Jan 09
9:45am ET
Optimistic Outlook for TG Therapeutics: Strategic Expansion and Financial Growth Potential
Jan 09
7:32am ET
Precision BioSciences says two deals with TG Therapeutics have $900M potential
Jan 09
7:23am ET
Precision BioSciences to get $47M in near term from TG Therapeutics deal
No recent press releases are available for TGTX
TGTX Financials
Key terms
Ad Feedback
TGTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TGTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
